๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
Xeris Biopharma Holdings, Inc. (XERS)
NASDAQ: XERS ยท Real-Time Price ยท USD
16.73
+0.11 (0.66%)
Nov 20, 2026, 9:49 AM EST - Market open

Xeris Biopharma Holdings Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
368.26291.85203.07163.91110.2549.59
Revenue Growth
38.37%43.72%23.89%48.68%122.32%142.67%
Gross Profit
321.8249.28166.24135.2787.6136.27
Operating Income
46.7824.9-33.65-44.01-81.94-105.5
Net Income
-6.50.55-54.84-62.26-94.66-122.73
Earnings Per Share
-0.040.00-0.37-0.45-0.70-1.55
EPS Growth
------

Cash & Debt

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
131.08111.0471.6272.45121.97102.43
Total Debt
226.07258.1271.45229.19198.0688.07
Net Cash (Debt)
-94.98-147.06-199.83-156.74-76.0914.37
Net Cash Growth
------69.28%
Net Cash Per Share
-0.55-0.85-1.36-1.14-0.560.18

Cash Flow & CapEx

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
73.6528.63-36.98-47.02-102.89-95.54
Capital Expenditures
-1.03-0.7-0.87-2.26-0.52-1.09
Free Cash Flow
72.6227.93-37.85-49.29-103.42-96.62
Free Cash Flow Growth
628.02%-----

Margins

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
87.38%85.41%81.86%82.52%79.47%73.14%
Operating Margin
12.70%8.53%-16.57%-26.85%-74.32%-212.74%
Pretax Margin
-1.76%0.19%-28.12%-38.74%-87.15%-247.48%
Profit Margin
-1.76%0.19%-27.00%-37.98%-85.86%-247.48%
FCF Margin
19.72%9.57%-18.64%-30.07%-93.80%-194.84%

Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingNov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
-2351.09----
Forward PE
51.8164.50----
P/FCF Ratio
41.8146.64----
PS Ratio
8.254.462.491.981.647.37